Insulin resistance: Site of the primary defect or how the current and the emerging therapies work

Journal of Basic and Clinical Physiology and Pharmacology

Volumn 9, Issue 2-4, 1998, Pages 281-294

  Kolaczynski, Jerzy W ^a   Caro, Jose F ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIHYPERTENSIVE AGENT; DEXFENFLURAMINE; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR; IMIDAZOLINE RECEPTOR; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN J2; SEROTONIN; THIAZOLIDINE DERIVATIVE; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ADRENERGIC SYSTEM; CENTRAL NERVOUS SYSTEM; ESSENTIAL HYPERTENSION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; VALVULAR HEART DISEASE;

ADIPOSE TISSUE; APPETITE DEPRESSANTS; DIABETES MELLITUS, TYPE 2; FEMALE; FENFLURAMINE; HUMANS; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN RESISTANCE; LIGANDS; METFORMIN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032456209     PISSN: 07926855     EISSN: 21910286     Source Type: Journal    
DOI: 10.1515/JBCPP.1998.9.2-4.281     Document Type: Article

References (63)

1. Bennett, PH. Epidemiology of diabetes mellitus. In: Rifkin H, Porte D Jr, eds. Ellenberg and Rifkin's Diabetes Mellitus. New York: Elsevier, 1990; 363–377.
2. Helmrich, SP, Ragland, DR, Leung, RW, Paffenbarger, RS Jr. Physical activity and reduced occurrence of non-insulin dependent diabetes mellitus. N Engl J Med 1991; 325: 147–152.
3. Ferrannini, E, Buzzigoli, G, Bonadonna, R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–357.
4. Reaven, GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
5. Modan, M, Halkin, H, Almog, S, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809–817.
6. Long, SD, O'Brien, K, MacDonald, KG Jr, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal preventional study. Diabetes Care 1994; 17: 372–375.
7. Hermann, LS, Melander, A. Biguanides: basic aspects and clinical uses. In: Alberti KGMM, Zimmet P, DeFronzo RA and Kern H, eds. International Textbook of Diabetes Mellitus. 2nd Ed. John Wiley & Sons Ltd., 1997; P841-864.
8. Stumvoll, M, Nuijhan, N, Periello, G, et al. Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med 1995; 333: 550–554.
9. Widen, EM, Eriksson, JG, Groop, LC. Metformin normalizes non-oxidative glucose metabolism in insulin resistant normoglycemic first degree relatives of patients with NIDDM. Diabetes 1992; 41: 354–358.
10. Velasquez, EM, Mendoza, S, Hamer, T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandro-genemia, and systolic blood pressure while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647–654.
11. Gugliano, D, DeRosa, N, DiMario, G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16: 1387–1390.
12. Groop, L, Widen, E, Franssila-Kallunki, A, et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in tjpe 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1989; 32: 599–605.
13. Tontonoz, P, Hu, E, Graves, RA, et al. PPAR-y2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8: 1224–1234.
14. Tontonoz, P, Hu, E, Spiegelman, BM. Stimulation of adipogenesis in fibroblasts by PPAR-y2, a lipid-activated transcription factor. Cell 1994; 79: 1147–1156.
15. Vidal-Puig, AJ, Considine, RV, Jimenez-Linan, M. Peroxisome-proliferator-activated receptor gene expression in human tissue: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416–2422.
16. Spiegelman, BM. PPAR-y: adipogenie regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507–514.
17. 12 14prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-y. Cell 1995; 83: 803–812.
18. Kliewer, SA, Lenhard, JM, Willson, TM. et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995; 83: 813–819.
19. Kliewer, SA, Sundseth, SS, Jones, SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997; 94: 4318–4323.
20. Hallakou, S, Doare, L, Foufelle, F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46: 1393–1399.
21. Hotamisligil, GH, Peraldi, P, Budavari, A, et al. lRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-a and obesity-induced insulin resistance. Science 1996; 271: 665–670.
22. Nolan, JJ, Olefsky, JM, Nyce, MR, et al. Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Diabetes 1996; 45: 1276–1278.
23. Boden, G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1996; 45: 3–10.
24. Connolly, HM, Crary, JL, McGoon, MD. et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581–588.
25. Abenhaim, L, Monde, Y, Brenot, T, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609–616.
26. Willey, KA, Molyneaux, LM, Yue, DK. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfen-fluramine therapy on glycaemic control. Diabetic Med 1994; 11: 701–704.
27. Willey, KA, Molyneaux, LM, Overland, JE, Yue, DK. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabetic Med 1992; 9: 341–343.
28. Salmela, PJ, Sotaniemi, EA, Viikari, J. Fenfluramine therapy in non-insulin dependent diabetic patients. Diabetes Care 1981; 4: 535–540.
29. Pestell, RG, Crock, PA, Ward, GM, et al. Fenfluramine increases insulin action in patients with NIDDM. Diabetes Care 1986; 12: 252–256.
30. Van Zwieten, PA. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and hemodynamics. J Hypertens 1997; 15 (Suppl 1): S3-S8.
31. Kaan, EC, Bruckner, R, Frohly, P, et al. Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995; 5 (Suppl 1): 19–27.
32. Reaven, GM, Lithell, H, Landsberg, L. Hypertension and associated metabolic abnormalities- the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374–381.
33. Julius, S, Gudbrandsson, T, Jamerson, K, et al. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9: 983–986.
34. Julius, S, Gudbrandsson, T. Early association of sympathetic overactivity, hypertension, insulin resistance, and coronary risk. J Cardiovasc Pharmacol 1992; 20 (Suppl 8): S40-S48.
35. Lithell, H. Moxonidine improves insulin resistance in obese, insulin resistant patients with hypertension. Presentation at the European Cardiology Society Meeting, Stockholm, August 1997.
36. Krentz, AJ, Evans, AJ. Commentary: Selective imidazoline receptor agonists for metabolic syndrome. Lancet 1998; 351: 152–153.
37. Vollenweider, P, Randlin, D, Tappy, L, et al. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 1994; 93: 2365–2371.
38. Anderson, EA, Hoffman, RP, Balon, TW, Sinkey, CA, Mark, AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1992; 90: 24–29.
39. Hausberg, M, Mark, AL, Hoffman, RP, Sinkey, CA, Anderson, EA. Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J Hypertens 1995; 13: 1015–1021.
40. Scherrer, U, Vollenweider, P, Randlin, D, et al. Suppression of insulin induced sympathetic activation and vasodilation by dexamethasone in humans. Circulation 1993; 88: 388–394.
41. Rothwell, NJ. Central effects of CRF on metabolism and energy balance. Neurosci Biobehav Rev 1990; 14; 263–271.
42. Boden, G, Chen, X, Kolaczynski, JW, Polansky, M. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J Clin Invest 1997; 100: 1107–1113.
43. Tsutsu, N, Nunoi, K, Kodama, T, et al. Lack of association between blood pressure and insulin in patients with insulinoma J Hypertens 1990; 8: 479–482.
44. Lembo, G, Capaldo, B, Rendina, V, et al. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am J Physiol 1994; 266: E242-E247.
45. Burant, CF, Treutelaar, MK, Buse, MG. In vitro and in vivo activation of the insulin receptor kinase in control and denervated skeletal muscle. J Biol Chem 1986; 261: 8985–8993
46. Spraul, M, Ravussin, E, Fontvieille, AM, et al. Reduced sympathetic nerve activity: a potential mechanism predisposing to body weight gain. J Clin Invest 1993; 92: 1730–1735.
47. Nuutila, P, Raitakari, M, Laine, H et al. Role of blood flow in regulating insulin-stimulated glucose uptake in humans. J Clin Invest 1996; 97: 1741–1747.
48. Scherrer, U, Randin, D, Vollenweider, P, Vollenweider, L, Nicod, P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511–2515.
49. Steinberg, HO, Brechtel, G, Johnson, A, Baron, AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172–1179.
50. Laakso, M, Edelman, SV, Brechtel, G, Baron, AD. Decreased effect of insulin to stimulate muscle blood flow in obese men: a novel mechanism of insulin resistance. J Clin Invest 1990; 85: 1844–1852.
51. Baron, AD. Hemodynamic actions of insulin. Am J Physiol 1994; 267: E187-E202.
52. Henrion, D, Laher, L. Insulin potentiates norepinephrine-induced vascular tone by activation of protein kinase C and tyrosine kinase. Can J Physiol Pharmacol 1994; 72: 849–854.
53. Ting, HH, Timimi, FK, Boles, KS, et al. Vitamin C improves endothelium dependent vasodilation in patients with non-insulin dependent diabetes mellitus. J Clin Invest 1996; 97: 22–28.
54. Sartori, C, Trueb, L, Scherrer, U. Insulin;s direct vasodilator action in humans is masked by sympathetic vasoconstrictor tone. Diabetes 1996; 45: 85A (Abstract).
55. Zeman, RJ, Ludemann, R, Easton, TG, Etlinger, JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a ß2-receptor agonist. Am J Physiol 1988; 254: E726-E732.
56. Lillioja, S, Young, AA, Cutler, CL, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987; 80: 415–424.
57. Kriketos, AD, Pan, DA, Lillioja, S, et al. Interrelationships between muscle morphology, insulin action and adiposity. Am J Physiol 1996; 270 (6 Pt 2): R1332-1339.
58. Krotkiewski, M, Seidell, JC. Bjorntorp, P. Glucose tolerance and hyperinsulinemia in obese women: role of adipose tissue distribution, muscle fibre characteristics and androgens. J Intern Med 1990; 228: 385–392.
59. Garvey, WT, Maianu, L, Hancock, JA, et al. Gene expression and GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes 1992; 41: 465–475.
60. Haynes, WG, Morgan, DA, Walsh, SA, et al. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100: 270–278.
61. Dunbar, JC, Hu, Y, Lu, H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997; 46: 2040–2043.
62. Considine, RV, Sinha, MK, Heiman, ML, et al. Serum immunoreactive leptin concentrations in normal weight and obese humans. N Engl J Med 1996; 334: 292–295.
63. Kolaczynski, JW, Ohannesian, J, Considine, RV, et al. Response of leptin to short-term and prolonged overfeeding in humans. J Clin Endocr Metab 1996; 81: 162–165.